UnitedHealth lifts 2025 profit forecast, aims for growth in 2026

UnitedHealth (UNH) raised its 2025 adjusted profit forecast to at least $16.25 per share, surpassing analyst estimates, after reporting third-quarter adjusted earnings of $2.92 per share that beat expectations by $0.13. This strong performance, attributed to keeping medical costs in check with a medical loss ratio of 89.9%, indicates that turnaround efforts under returning CEO Stephen Hemsley are gaining momentum. The company also signaled intentions for "durable and accelerating growth" in 2026, prompting a premarket share surge of over 4% and positive movement for rivals, despite the broader industry still facing elevated medical costs.

Analysis

UnitedHealth (UNH) reported robust third-quarter adjusted earnings of $2.92 per share, surpassing analyst estimates by $0.13, and subsequently raised its 2025 adjusted profit forecast to at least $16.25 per share, exceeding both prior guidance and analyst consensus. This positive revision, attributed to effective medical cost management with a medical loss ratio of 89.9%, signals a potential floor for investor expectations and reflects a deliberate, conservative approach by management. The company also articulated a strategic focus on achieving "durable and accelerating growth in 2026 and beyond," with analysts projecting $17.59 per share for 2026.

The improved outlook and Q3 performance underscore the initial success of turnaround efforts under returning CEO Stephen Hemsley, who rejoined in May following a period of significant challenges for the company. This management shakeup appears to be restoring investor confidence, as evidenced by UNH's over 4% premarket share surge and a 2% rise in shares of rivals CVS Health and Elevance Health. The market reaction suggests an optimistic view on the company's trajectory under new leadership.

While the Optum health services unit's revenue remained flat year-over-year at $25.9 billion, the Optum Rx pharmacy benefit manager segment demonstrated strong growth, with revenue increasing 16% to $39.7 billion, partly driven by higher prescription volumes. Despite these internal strengths, the broader healthcare industry continues to face elevated medical costs, a persistent challenge for over two years, which UNH is actively managing to keep in check.

Key Decisions for Investors

• Investors should closely monitor UnitedHealth's execution on its raised 2025 profit guidance and the progress towards its stated 2026 growth acceleration, particularly regarding sustained medical cost containment and Optum Rx's continued performance.
• Evaluate the long-term sustainability of the management turnaround under CEO Hemsley, considering the company's recent history of operational challenges and the ongoing industry-wide pressure from elevated medical costs.
• Assess the potential for positive sentiment and operational improvements at UNH to translate into broader sector strength, particularly for competitors like CVS Health and Elevance Health, while acknowledging shared industry headwinds.